Should routine HPV vaccination programs include males 25-29 years? A systematic review and global meta-analysis.

ABSTRACT:

Background

Males aged 25-29 years represent the peak transmission group for human papillomavirus (HPV). However, they are often excluded from routine vaccination programs due to concerns regarding cost-effectiveness and limited efficacy data. This study synthesized evidence on vaccine efficacy and herd effects to support the potential expansion of HPV vaccination to this demographic.

Methods

This systematic review and meta-analysis searched PubMed, Embase, and the Cochrane Library from January 1, 2007, to February 1, 2025. We included randomized controlled trials and observational studies that reported on the efficacy of the 4vHPV vaccine against incident HPV infections (4vHPV-type [6/11/16/18] or any HPV) in males, as well as herd effects on anogenital warts (AGW) in unvacc

SUBMITTER: Wan S 

PROVIDER: S-EPMC12642371 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature